Vivek Goodoory
@VivekGoodoory
Followers
209
Following
402
Media
6
Statuses
213
Gastro registrar | PhD Candidate | 🇲🇺🇬🇧
United Kingdom
Joined December 2016
Huge thank you to our departing @FrontGastro_BMJ trainee editors 2023-2025. Vivek, Philip, Rex, Gio, James and Mohsen have been fantastic representatives of the journal and @PhilSmithIsBack @RMBeattie50 and the whole #FGTeam are very grateful for all their hard work and efforts.
0
4
16
Very grateful to all our departing @FrontGastro_BMJ trainee editors 2023-2025 - thank you so much for your hard work and efforts! We will keep in touch and thank you in advance for supporting the new trainee editors! @VivekGoodoory @RexWHHui @DrJMKennedy @sheiybani @MohsenSubhani
Huge thank you to our departing @FrontGastro_BMJ trainee editors 2023-2025. Vivek, Philip, Rex, Gio, James and Mohsen have been fantastic representatives of the journal and @PhilSmithIsBack @RMBeattie50 and the whole #FGTeam are very grateful for all their hard work and efforts.
1
4
15
🎉 Happy New Year from all at FG! Kick off your 2025 with a resolution to keep up to date with all our #onlinefirst content at https://t.co/FPfOTigvL5
@PhilSmithIsBack @sheiybani
@VivekGoodoory @DunnePdj @RexWHHui @OTavabie @dr_aditi_kumar
0
8
17
The conventional subtyping of Rome IV #IBS is probably an oversimplification of a complex and multidimensional condition.
1
2
2
1
2
2
We have also previously shown that this novel subgrouping of Rome IV #IBS can be used to predict the #prognosis of IBS (symptom severity), health-care use (consultation behaviour, prescribing, and costs), and #impact (QoL, work and productivity, ADLs, and income).
1
2
2
The following approaches for first-line and second-line treatment could be considered according to these subgroups
1
2
2
In the 12th and final #12paperstoChristmas series, we discussed the #personalisation of therapy in #IBS in @LancetGastroHep. Full paper available from:
thelancet.com
Irritable bowel syndrome (IBS) is a common disorder of gut–brain interaction characterised by symptoms of abdominal pain, occurring at least 1 day per week, and a change in stool frequency or form....
1
3
5
Our results necessitate further research into the possible involvement of the #gut–#brain #interaction in #non-#coeliac #gluten #sensitivity
1
1
1
In the 6th #12paperstoChristmas series, we reported a #RCT investigating the effects of expectancy versus actual #gluten intake on symptoms in people with non- #coeliac #glutensensitivity in @LancetGastroHep. Full paper available from:
thelancet.com
The combination of expectancy and actual gluten intake had the largest effect on gastrointestinal symptoms, reflecting a nocebo effect, although an additional effect of gluten cannot be ruled out....
1
1
3
Therapies other than #TFUO should be considered as first-line therapy in women with IBD of childbearing age. TFUO may be appropriate for women of childbearing age after failure of, intolerance or contraindications to one biological agent.
1
2
3
Women receiving #TFUO should cease therapy in time to establish clinical remission for at least 3 months prior to #conception.
1
1
2
1
1
2
In the 11th #12paperstoChristmas series, we evaluated the appropriateness of novel small molecules #tofacitinib, #filgotinib, #upadacitinib and #ozanimod (#TFUO) in #women of #childbearing age with #IBD in @TAGastroenterol. Full paper available from:
journals.sagepub.com
Background: Many women of childbearing age with inflammatory bowel disease (IBD) require advanced therapies. While biologics are largely low risk during pregnan...
1
4
4
In the 10th #12paperstoChristmas series, we reviewed #postprandial symptoms in #DGBI and their potential as a #treatment target in @Gut_BMJ. Full paper available from:
gut.bmj.com
Postprandial, or meal-related, symptoms, such as abdominal pain, early satiation, fullness or bloating, are often reported by patients with disorders of gut-brain interaction, including functional...
1
4
5
1
4
6
Our data indicate that the FADS Indel at #rs66698963 is a key functional polymorphism that predicts n–3 HUFA efficacy for colorectal polyp risk reduction in a randomized trial of EPA
1
2
2
0
2
2
When data for global #IBS symptoms were pooled, drugs (both #ebastine and #ketotifen) acting on #histamine 1 receptors were significantly more effective than placebo.
1
2
2